ID   ER-SQ20B
AC   CVCL_EI29
DR   cancercelllines; CVCL_EI29
DR   GEO; GSM1524319
DR   GEO; GSM1524320
DR   GEO; GSM1524321
DR   Wikidata; Q54832420
RX   PubMed=25888065;
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Larynx; UBERON=UBERON_0001737.
DI   NCIt; C4044; Laryngeal squamous cell carcinoma
DI   ORDO; Orphanet_494550; Squamous cell carcinoma of the larynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7138 ! SQ-20B
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 9
//
RX   PubMed=25888065; DOI=10.1016/j.molonc.2015.03.008; PMCID=PMC4523436;
RA   Stanam A., Love-Homan L., Joseph T.S., Espinosa-Cotton M.,
RA   Simons A.L.;
RT   "Upregulated interleukin-6 expression contributes to erlotinib
RT   resistance in head and neck squamous cell carcinoma.";
RL   Mol. Oncol. 9:1371-1383(2015).
//